Publication: HALVING OF MORTALITY OF SEVERE MELIOIDOSIS BY CEFTAZIDIME
Issued Date
1989-09-23
Resource Type
ISSN
01406736
Other identifier(s)
2-s2.0-0024449456
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet. Vol.334, No.8665 (1989), 697-701
Suggested Citation
N. J. White, W. Chaowagul, V. Wuthiekanun, D. A.B. DANCE, Y. Wattanagoon, N. Pitakwatchara HALVING OF MORTALITY OF SEVERE MELIOIDOSIS BY CEFTAZIDIME. The Lancet. Vol.334, No.8665 (1989), 697-701. doi:10.1016/S0140-6736(89)90768-X Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/15795
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
HALVING OF MORTALITY OF SEVERE MELIOIDOSIS BY CEFTAZIDIME
Other Contributor(s)
Abstract
An open randomised trial was conducted to compare ceftazidime (120 mg/kg/day) with "conventional therapy" (chloramphenicol 100 mg/kg/day, doxycycline 4 mg/kg/day, trimethoprim 10 mg/kg/day, and sulphamethoxazole 50 mg/kg/day) in the treatment of severe melioidosis. A paired restricted sequential trial designed to detect a reduction in mortality from 80 to 40% in culture-positive patients surviving > 48 hours was stopped after 22 months. Of the 161 patients entered into the study, 65 had bacteriologically confirmed melioidosis and 54 of these were septicaemic. Ceftazidime treatment was associated with a 50% (95% CI 19-81%) lower overall mortality than conventional treatment (74% vs 37%; p=0·009) and should now become the treatment of choice for severe melioidosis. © 1989.